LF
NBIX icon

Lansforsakringar Fondforvaltning’s Neurocrine Biosciences NBIX Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.52M Sell
26,792
-5,096
-16% -$756K 0.02% 468
2026
Q1 		$4.2M Hold
31,888
– – 0.02% 417
2025
Q4 		$4.52M Buy
31,888
+397
+1% +$57.5K 0.02% 427
2025
Q3 		$4.42M Hold
31,491
– – 0.02% 422
2025
Q2 		$3.96M Sell
31,491
-955
-3% -$110K 0.02% 430
2025
Q1 		$3.59M Hold
32,446
– – 0.02% 441
2024
Q4 		$4.43M Buy
+32,446
New +$4.01M 0.02% 420

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lansforsakringar Fondforvaltning's NBIX Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, selling an estimated $756K and leaving 26,792 shares worth $4.52M. The position accounts for 0.02% of the portfolio, ranked #468.

Lansforsakringar Fondforvaltning first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.52M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Lansforsakringar Fondforvaltning held 26,792 shares of Neurocrine Biosciences worth $4.52M as of Q2 2026.
  • Lansforsakringar Fondforvaltning sold 5,096 Neurocrine Biosciences shares in Q2 2026, an estimated $756K.
  • Neurocrine Biosciences made up 0.02% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #468 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Lansforsakringar Fondforvaltning's Neurocrine Biosciences position peaked at $4.52M in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.